Vantage BioTrials Awarded Phase 1b ARDS Trial

November 1, 2023, Montréal, Canada – Vantage BioTrials, a full-service Contract Research Organization (CRO), has partnered with a US-based biotech to lead all clinical trial management activities of their Phase Ib Dose Escalation followed by Phase II randomized, placebo controlled, blinded end-point trial in patients with Acute Respiratory Distress Syndrome (ARDS), including COVID-19 patients.

The dose escalation phase of the study will inform the safety profile of the Sponsor’s Investigational Product (IP) prior to an evaluation in patients at risk for mechanical ventilation in the dose expansion phase. Overall, the study will establish dosing guidelines for a larger study in acutely ill, hypoxemic patients with ARDS.

“We are again excited to contribute our expertise towards this important initiative for the advancement of effective therapies in patients affected with ARDS.  We look forward to making a positive impact and achieving all study milestones for our US biotech Sponsor”, said Vatche Bartekian, President of Vantage BioTrials. “We are continually challenging ourselves by providing quality outcomes and strengthening our partnerships with leading North American hospitals. Most importantly, we continue to ensure the safety and well-being of patients with respiratory distress through our quality by design and risk-based approach to managing these types of challenging clinical trials”, added Mr. Bartekian.

About Vantage BioTrials

Vantage BioTrials is a Contract Research Organization (CRO) that uses innovative clinical trial management strategies for the life science industry with a focus on patient safety & advancing new therapies to market. We offer pharmaceutical, biotech & medical device companies a complete and integrated set of full service clinical trial management solutions at a competitive value.

Contact us today at [email protected] and discover how we can add value to your next clinical trial program.

Tags: ,
Categories:News-homepage, news-pressroom